{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:12:18Z","timestamp":1793913138152,"version":"4.8.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"NEAT-ID Foundation"},{"name":"St Stephen's Aids Trust"},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CIBERINFEC -Consorcio Centro de Investigaci\u00f3n Biom\u00e9dica en Red"},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministerio de Ciencia e Innovaci\u00f3n and Uni\u00f3n Europea\u2014NextGenerationEU"},{"name":"Spanish AIDS Research Network","award":["RD16\/0025\/0001"],"award-info":[{"award-number":["RD16\/0025\/0001"]}]},{"name":"ISCIII- Subdirecci\u00f3n General de Evaluaci\u00f3n"},{"DOI":"10.13039\/501100008530","name":"Fondo Europeo de Desarrollo Regional","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Integrase inhibitors have been recently linked to a higher risk for hypertension. In NEAT022 randomized trial, virologically suppressed persons with human immunodeficiency virus (HIV, PWH) with high cardiovascular risk switched from protease inhibitors to dolutegravir either immediately (DTG-I) or after 48 weeks (DTG-D).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Primary endpoint was incident hypertension at 48 weeks. Secondary endpoints were changes in systolic (SBP) and diastolic (DBP) blood pressure; adverse events and discontinuations associated with high blood pressure; and factors associated with incident hypertension.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At baseline, 191 (46.4%) participants had hypertension and 24 persons without hypertension were receiving antihypertensive medications for other reasons. In the 197 PWH (n = 98, DTG-I arm; n = 99, DTG-D arm) without hypertension or antihypertensive agents at baseline, incidence rates per 100 person-years were 40.3 and 36.3 (DTG-I) and 34.7 and 52.0 (DTG-D) at 48 (P = .5755) and 96 (P = .2347) weeks. SBP or DBP changes did not differed between arms. DBP (mean, 95% confidence interval) significantly increased in both DTG-I (+2.78 mmHg [1.07\u20134.50], P = .0016) and DTG-D (+2.29 mmHg [0.35\u20134.23], P = .0211) arms in the first 48 weeks of exposure to dolutegravir. Four (3 under dolutegravir, 1 under protease inhibitors) participants discontinued study drugs due to adverse events associated with high blood pressure. Classical factors, but not treatment arm, were independently associated with incident hypertension.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>PWH at high risk for cardiovascular disease showed high rates of hypertension at baseline and after 96 weeks. Switching to dolutegravir did not negatively impact on the incidence of hypertension or blood pressure changes relative to continuing protease inhibitors.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciad297","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T22:07:22Z","timestamp":1684534042000},"page":"991-1009","source":"Crossref","is-referenced-by-count":25,"title":["Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial"],"prefix":"10.1093","volume":"77","author":[{"given":"Abiu","family":"Sempere","sequence":"first","affiliation":[{"name":"Hospital Cl\u00ednic-IDIBAPS, University of Barcelona , Barcelona , Spain"},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambert","family":"Assoumou","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'Epid\u00e9miologie, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gonz\u00e1lez-Cord\u00f3n","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic-IDIBAPS, University of Barcelona , Barcelona , Spain"},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Waters","sequence":"additional","affiliation":[{"name":"Mortimer Market Centre, Central & North West London National Health Service (NHS) Foundation Trust , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Rusconi","sequence":"additional","affiliation":[{"name":"Ospedale Luigi Sacco, Universit\u00e0 degli Studi , Milano , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Domingo","sequence":"additional","affiliation":[{"name":"Mortimer Market Centre, Central & North West London National Health Service (NHS) Foundation Trust , London , United Kingdom"},{"name":"Hospital de Sant Pau , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gompels","sequence":"additional","affiliation":[{"name":"North Bristol NHS Trust , Bristol , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"de Wit","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire Saint-Pierre , Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Raffi","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire , Nantes , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Stephan","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum-Infektionskrankheiten , Frankfurt , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Masi\u00e1","sequence":"additional","affiliation":[{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"},{"name":"Hospital General Universitario de Elche , Elche , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Rockstroh","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum , Bonn , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Katlama","sequence":"additional","affiliation":[{"name":"H\u00f4pital Universitaire Piti\u00e9 Salp\u00eatri\u00e8re , Service des Maladies Infectieuses et Tropicales , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg M N","family":"Behrens","sequence":"additional","affiliation":[{"name":"Medizinische Hochschule , Hannover , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Moyle","sequence":"additional","affiliation":[{"name":"Chelsea and Westminster Hospital NHS Foundation Trust , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Johnson","sequence":"additional","affiliation":[{"name":"Royal Free London NHS Foundation Trust , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Fox","sequence":"additional","affiliation":[{"name":"Guy's & St Thomas\u2019 NHS Foundation Trust , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00fcrgen","family":"Stellbrink","sequence":"additional","affiliation":[{"name":"Infektionsmedizinisches Centrum , Hamburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Guaraldi","sequence":"additional","affiliation":[{"name":"University of Modena and Reggio Emilia , Modena , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Florence","sequence":"additional","affiliation":[{"name":"Universitair Ziekenhuis Antwerpen , Antwerp , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Esser","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum, Universit\u00e4t Duisburg-Essen , Essen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Gatell","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Pozniak","sequence":"additional","affiliation":[{"name":"Chelsea and Westminster Hospital NHS Foundation Trust , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'Epid\u00e9miologie, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique , Paris , France"},{"name":"Mortimer Market Centre, Central & North West London National Health Service (NHS) Foundation Trust , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the NEAT 022 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linos","family":"Vandekerckhove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Caluw\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"De Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coca","family":"Necsoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Florence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"and","family":"Maartje Van Frankenhuijsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"2023100601372064800_ciad297-B1","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1097\/HJH.0000000000002446","article-title":"Global burden of hypertension among people living with HIV in the era of increased life expectancy: a systematic review and meta-analysis","volume":"38","author":"Bigna","year":"2020","journal-title":"J Hypertens"},{"key":"2023100601372064800_ciad297-B2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/ajh\/hpz132","article-title":"Role of inflammatory biomarkers in the prevalence and incidence of hypertension among HIV-positive participants in the START trial","volume":"33","author":"Ghazi","year":"2020","journal-title":"Am J Hypertens"},{"key":"2023100601372064800_ciad297-B3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/jch.12029","article-title":"Low nadir CD4 cell count predicts sustained hypertension in HIV-infected individuals","volume":"15","author":"Manner","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2023100601372064800_ciad297-B4","doi-asserted-by":"crossref","DOI":"10.1177\/2050312120924892","article-title":"The association of nadir CD4-T cell count and endothelial dysfunction in a healthy HIV cohort without major cardiovascular risk factors","volume":"8","author":"Mogadam","year":"2020","journal-title":"SAGE Open Med"},{"key":"2023100601372064800_ciad297-B5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1468-1293.2005.00333.x","article-title":"Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients: a prospective study in a cohort of naive patients","volume":"7","author":"Palacios","year":"2006","journal-title":"HIV Med"},{"key":"2023100601372064800_ciad297-B6","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/hiv.13273","article-title":"Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium","volume":"23","author":"Byonanebye","year":"2022","journal-title":"HIV Med"},{"key":"2023100601372064800_ciad297-B7","doi-asserted-by":"crossref","first-page":"ofz491","DOI":"10.1093\/ofid\/ofz491","article-title":"Short-term increase in risk of overweight and concomitant systolic blood pressure elevation in treatment-na\u00efve persons starting INSTI-based antiretroviral therapy","volume":"6","author":"Galdamez","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2023100601372064800_ciad297-B8","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/AOG.0000000000003584","article-title":"Combination antiretroviral therapy and hypertensive disorders of pregnancy","volume":"134","author":"Saums","year":"2019","journal-title":"Obstet Gynecol"},{"key":"2023100601372064800_ciad297-B9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/QAI.0000000000002447","article-title":"Metabolic changes associated with the use of integrase strand transfer inhibitors among virally controlled women","volume":"85","author":"Summers","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023100601372064800_ciad297-B10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.11604\/pamj.2021.39.237.29718","article-title":"Prevalence and correlates of hypertension in HIV-positive adults from the livingstone central hospital, Zambia","volume":"39","author":"Musekwa","year":"2021","journal-title":"Pan Afr Med J"},{"key":"2023100601372064800_ciad297-B11","doi-asserted-by":"crossref","first-page":"101836","DOI":"10.1016\/j.eclinm.2023.101836","article-title":"Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South Africa","volume":"57","author":"Brennan","year":"2023","journal-title":"eClinicalMedicine"},{"key":"2023100601372064800_ciad297-B12","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/01.aids.0000222074.45372.00","article-title":"Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy","volume":"20","author":"Crane","year":"2006","journal-title":"AIDS"},{"key":"2023100601372064800_ciad297-B13","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1468-1293.2009.00699.x","article-title":"Effects of HIV status and antiretroviral therapy on blood pressure","volume":"10","author":"Wilson","year":"2009","journal-title":"HIV Med"},{"key":"2023100601372064800_ciad297-B14","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1089\/aid.2021.0213","article-title":"Risk factors for incident hypertension within 1 year of initiating antiretroviral therapy among people with HIV","volume":"38","author":"Siddiqui","year":"2022","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2023100601372064800_ciad297-B15","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/hiv.12639","article-title":"Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV-positive persons: the data collection on adverse events of anti-HIV drugs (D:A:D) study","volume":"19","author":"Hatleberg","year":"2018","journal-title":"HIV Med"},{"key":"2023100601372064800_ciad297-B16","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1097\/QAD.0000000000001675","article-title":"Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk","volume":"31","author":"Gatell","year":"2017","journal-title":"AIDS"},{"key":"2023100601372064800_ciad297-B17","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/cid\/ciy505","article-title":"Immediate versus deferred switching from a boosted protease inhibitor-based regimen to a dolutegravir-based regimen in virologically suppressed patients with high cardiovascular risk or age \u226550 years: final 96-week results of the NEAT022 study","volume":"68","author":"Gatell","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023100601372064800_ciad297-B18","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur Heart J"},{"key":"2023100601372064800_ciad297-B19","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2023100601372064800_ciad297-B20","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","article-title":"2020 International Society of Hypertension global hypertension practice guidelines","volume":"38","author":"Unger","year":"2020","journal-title":"J Hypertens"},{"key":"2023100601372064800_ciad297-B21","first-page":"e426","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"138","author":"Whelton","year":"2018","journal-title":"Circulation"},{"key":"2023100601372064800_ciad297-B22","volume-title":"Antihypertensive medications","author":"Khalil","year":"2023"},{"key":"2023100601372064800_ciad297-B23","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/0140-6736(90)90878-9","article-title":"Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias","volume":"335","author":"MacMahon","year":"1990","journal-title":"Lancet"},{"key":"2023100601372064800_ciad297-B24","doi-asserted-by":"crossref","first-page":"e952","DOI":"10.1097\/MD.0000000000000952","article-title":"Prevalence and incidence of hypertension in the general adult population: results of the CARLA cohort study","volume":"94","author":"Lacruz","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"2023100601372064800_ciad297-B25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0091-7435(87)90087-9","article-title":"Incidence and precursors of hypertension in young adults: the Framingham Offspring Study","volume":"16","author":"Garrison","year":"1987","journal-title":"Prev Med"},{"key":"2023100601372064800_ciad297-B26","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/COH.0000000000000406","article-title":"Hypertension in people living with HIV","volume":"12","author":"van Zoest","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"key":"2023100601372064800_ciad297-B27","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/jch.13933","article-title":"Regression to the mean in home blood pressure: analyses of the BP GUIDE study","volume":"22","author":"Wang","year":"2020","journal-title":"J Clin Hypertens"},{"key":"2023100601372064800_ciad297-B28","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.amjmed.2007.06.021","article-title":"Predictors of significant short-term increases in blood pressure in a community-based population","volume":"120","author":"Aiyer","year":"2007","journal-title":"Am J Med"},{"key":"2023100601372064800_ciad297-B29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1161\/01.HYP.37.2.187","article-title":"Association between smoking and blood pressure: evidence from the health survey for England","volume":"37","author":"Primatesta","year":"2001","journal-title":"Hypertension"},{"key":"2023100601372064800_ciad297-B30","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1186\/s12889-017-4802-x","article-title":"The association between smoking and blood pressure in men: a cross-sectional study","volume":"17","author":"Li","year":"2017","journal-title":"BMC Public Health"},{"key":"2023100601372064800_ciad297-B31","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/cid\/ciac827","article-title":"Limited weight impact after switching from boosted protease inhibitors to dolutegravir in persons with HIV with high cardiovascular risk: a post hoc analysis of the 96-week NEAT-022 randomized trial","volume":"76","author":"Waters","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023100601372064800_ciad297-B32","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1097\/QAD.0000000000002930","article-title":"Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes","volume":"35","author":"McCann","year":"2021","journal-title":"AIDS"},{"key":"2023100601372064800_ciad297-B33","author":"European AIDS Clinical Society"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad297\/50607691\/ciad297.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/7\/991\/51905919\/ciad297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/7\/991\/51905919\/ciad297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T01:38:10Z","timestamp":1696556290000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/77\/7\/991\/7173995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,5,19]]},"published-print":{"date-parts":[[2023,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad297","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10,1]]},"published":{"date-parts":[[2023,5,19]]}}}